Aflatoxin B1 - a potential endocrine disruptor - up-regulates CYP19A1 in JEG-3 cells

Toxicology Letters

Volumn 202, Issue 3, 2011, Pages 161-167

  Storvik, Markus ^a   Huuskonen, Pasi ^a   Kyllönen, Taija ^a   Lehtonen, Sarka ^a   El Nezami, Hani ^b   Auriola, Seppo ^a   Pasanen, Markku ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Aflatoxicol; Aflatoxin B1; Aromatase; Endocrine disruptor; JEG 3; Placenta

Indexed keywords

AFLATOXIN B1; AROMATASE; CYTOCHROME P450 3A4; ESTROGEN RECEPTOR; FINROZOLE; TAMOXIFEN;

ARTICLE; CELL LINE; CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 79954599433     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2011.01.028     Document Type: Article

References (36)

1. Abdulrazzaq Y.M., Osman N., Ibrahim A. Fetal exposure to aflatoxins in the United Arab Emirates. Ann. Trop. Paediatr. 2002, 22:3-9.
2. Abdulrazzaq Y.M., Osman N., Yousif Z.M., Trad O. Morbidity in neonates of mothers who have ingested aflatoxins. Ann. Trop. Paediatr. 2004, 24:145-151.
3. Bulun S.E., Sebastian S., Takayama K., Suzuki T., Sasano H., Shozu M. The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. J. Steroid Biochem. Mol. Biol. 2003, 86:219-224.
4. Bulun S.E., Simpson E.R. Regulation of aromatase expression in human tissues. Breast Cancer Res. Treat. 1994, 30:19-29.
5. Eaton D.L., Gallagher E.P. Mechanisms of aflatoxin carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 1994, 34:135-172.
6. Gallagher E.P., Wienkers L.C., Stapleton P.L., Kunze K.L., Eaton D.L. Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1. Cancer Res. 1994, 54:101-108.
7. Guengerich F.P., Johnson W.W., Shimada T., Ueng Y.F., Yamazaki H., Langouet S. Activation and detoxication of aflatoxin B1. Mutat. Res. 1998, 402:121-128.
8. Hakkola J., Pasanen M., Hukkanen J., Pelkonen O., Maenpaa J., Edwards R.J., Boobis A.R., Raunio H. Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem. Pharmacol. 1996, 51:403-411.
9. Hakkola J., Raunio H., Purkunen R., Pelkonen O., Saarikoski S., Cresteil T., Pasanen M. Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. Biochem. Pharmacol. 1996, 52:379-383.
10. Huang H., Leung L.K. Bisphenol A downregulates CYP19 transcription in JEG-3 cells. Toxicol. Lett. 2009, 189:248-252.
11. Huuskonen P., Storvik M., Reinisalo M., Honkakoski P., Rysa J., Hakkola J., Pasanen M. Microarray analysis of the global alterations in the gene expression in the placentas from cigarette-smoking mothers. Clin. Pharmacol. Ther. 2008, 83:542-550.
12. Ibrahim A.R., Abul-Hajj Y.J. Aromatase inhibition by flavonoids. J. Steroid Biochem. Mol. Biol. 1990, 37:257-260.
13. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. IARC Monogr. Eval. Carcinog. Risks Hum. 2002, 82:1-556.
14. Kumar P., Kamat A., Mendelson C.R. Estrogen receptor alpha (ERalpha) mediates stimulatory effects of estrogen on aromatase (CYP19) gene expression in human placenta. Mol. Endocrinol. 2009, 23:784-793.
15. Meinhardt U., Mullis P.E. The aromatase cytochrome P-450 and its clinical impact. Horm. Res. 2002, 57:145-152.
16. Monteiro R., Azevedo I., Calhau C. Modulation of aromatase activity by diet polyphenolic compounds. J. Agric. Food Chem. 2006, 54:3535-3540.
17. Myllynen P., Pasanen M., Vahakangas K. The fate and effects of xenobiotics in human placenta. Expert Opin. Drug Metab. Toxicol. 2007, 3:331-346.
18. Newbold R.R., Padilla-Banks E., Jefferson W.N. Adverse effects of the model environmental estrogen diethylstilbestrol are transmitted to subsequent generations. Endocrinology 2006, 147:S11-S17.
19. Numazawa M., Komatsu S., Tominaga T., Yamashita K. Structure-activity relationships of estrogen derivatives as aromatase inhibitors. Effects of heterocyclic substituents. Chem. Pharm. Bull. (Tokyo) 2008, 56:1304-1309.
20. Obolenskaya M.Y., Teplyuk N.M., Divi R.L., Poirier M.C., Filimonova N.B., Zadrozna M., Pasanen M.J. Human placental glutathione S-transferase activity and polycyclic aromatic hydrocarbon DNA adducts as biomarkers for environmental oxidative stress in placentas from pregnant women living in radioactivity- and chemically-polluted regions. Toxicol. Lett. 2010, 196:80-86.
21. Paakki P., Stockmann H., Kantola M., Wagner P., Lauper U., Huch R., Elovaara E., Kirkinen P., Pasanen M. Maternal drug abuse and human term placental xenobiotic and steroid metabolizing enzymes in vitro. Environ. Health Perspect. 2000, 108:141-145.
22. Partanen H.A., El-Nezami H.S., Leppanen J.M., Myllynen P.K., Woodhouse H.J., Vahakangas K.H. Aflatoxin B1 transfer and metabolism in human placenta. Toxicol. Sci. 2010, 113:216-225.
23. Pasanen M. The expression and regulation of drug metabolism in human placenta. Adv. Drug Deliv. Rev. 1999, 38:81-97.
24. Pasanen M. Human placental aromatase activity: use of a C18 reversed-phase cartridge for separation of tritiated water or steroid metabolites in placentas from both smoking and non-smoking mothers in vitro. Biol. Res. Pregnancy Perinatol. 1985, 6:94-99.
25. Polychronaki N., Turner C.P., Mykkanen H., Gong Y., Amra H., Abdel-Wahhab M., El-Nezami H. Determinants of aflatoxin M1 in breast milk in a selected group of Egyptian mothers. Food Addit. Contam. 2006, 23:700-708.
26. Prins G.S. Estrogen imprinting: when your epigenetic memories come back to haunt you. Endocrinology 2008, 149:5919-5921.
27. Rawn S.M., Cross J.C. The evolution, regulation, and function of placenta-specific genes. Annu. Rev. Cell Dev. Biol. 2008, 24:159-181.
28. Saarinen N., Joshi S.C., Ahotupa M., Li X., Ammala J., Makela S., Santti R. No evidence for the in vivo activity of aromatase-inhibiting flavonoids. J. Steroid Biochem. Mol. Biol. 2001, 78:231-239.
29. Salhab A.S., Edwards G.S. Comparative in vitro metabolism of aflatoxicol by liver preparations from animals and humans. Cancer Res. 1977, 37:1016-1021.
30. Sanderson J.T. Placental and fetal steroidogenesis. Methods Mol. Biol. 2009, 550:127-136.
31. Sawada M., Kitamura R., Norose T., Kitada M., Itahashi K., Kamataki T. Metabolic activation of aflatoxin B1 by human placental microsomes. J. Toxicol. Sci. 1993, 18:129-132.
32. Schiessl B., Mylonas I., Hantschmann P., Kuhn C., Schulze S., Kunze S., Friese K., Jeschke U. Expression of endothelial NO synthase, inducible NO synthase, and estrogen receptors alpha and beta in placental tissue of normal, preeclamptic, and intrauterine growth-restricted pregnancies. J. Histochem. Cytochem. 2005, 53:1441-1449.
33. Simpson E.R. Aromatase: biologic relevance of tissue-specific expression. Semin. Reprod. Med. 2004, 22:11-23.
34. Swedenborg E., Pongratz I. AhR and ARNT modulate ER signaling. Toxicology 2010, 268:132-138.
35. Wang Y., Leung L.K. Pharmacological concentration of resveratrol suppresses aromatase in JEG-3 cells. Toxicol. Lett. 2007, 173:175-180.
36. Wong J.J., Hsieh D.P. Mutagenicity of aflatoxins related to their metabolism and carcinogenic potential. Proc. Natl. Acad. Sci. U.S.A. 1976, 73:2241-2244.